Bcl-xL Antisense Oligonucleotides Sensitize Colon Cancer Cells
Author Information
Author(s): Wacheck V, Selzer E, Günsberg P, Lucas T, Meyer H, Thallinger C, Monia B P, Jansen B
Primary Institution: University of Vienna
Hypothesis
Downregulation of Bcl-xL by antisense oligonucleotides may sensitize colon cancer cells to ionizing radiation or cisplatin.
Conclusion
Bcl-xL antisense oligonucleotides significantly enhance the sensitivity of colon cancer cells to radiation and chemotherapy.
Supporting Evidence
- Bcl-xL antisense oligonucleotides significantly reduced Bcl-xL expression by almost 50%.
- The combination of Bcl-xL AS oligonucleotides and IR resulted in a pronounced increase of apoptotic cell death.
- Caco-2 cells treated with Bcl-xL AS oligonucleotides and cisplatin showed more than a 75% reduction in cell viability.
- Clonogenic survival was significantly reduced by at least two-thirds when combining Bcl-xL AS oligonucleotides with IR.
Takeaway
Scientists found that a special treatment can help cancer cells die when they are exposed to radiation or medicine, making the treatment work better.
Methodology
Caco-2 colon cancer cells were treated with Bcl-xL antisense oligonucleotides and exposed to ionizing radiation or cisplatin, followed by assessments of cell viability and apoptosis.
Limitations
The study primarily focused on in vitro experiments, and the clinical applicability of the findings needs further investigation.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website